Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lenvatinib Clear all
Completed Phase 1 Interventional

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

NCT03524326
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma
Interventions
Lenvatinib Pill, Cetuximab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

NCT02686164
View directory record Official record
Conditions
Tumors
Interventions
Lenvatinib, Midazolam
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Detroit, Michigan • The Bronx, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

NCT03245151
View directory record Official record
Conditions
Recurrent and Refractory Solid Tumors
Interventions
Lenvatinib, Everolimus
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years to 21 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

NCT02792829
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Results available

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

NCT03006926
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
lenvatinib, pembrolizumab (200 mg)
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Francisco, California • Santa Monica, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

NCT04428151
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Lenvatinib, Pembrolizumab, Docetaxel, Capecitabine, Paclitaxel, Cetuximab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
55
States / cities
Duarte, California • Los Angeles, California • New Haven, Connecticut + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)

NCT03776136
View directory record Official record
Conditions
Advanced Melanoma
Interventions
lenvatinib, pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Chandler, Arizona • Santa Monica, California • Park Ridge, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 11, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

NCT05012371
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Cabozantinib, Everolimus, Lenvatinib, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

NCT01433991
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Golvatinib, Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Early Phase 1 Interventional

Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

NCT05188118
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Cabozantinib, Ipilimumab, Nivolumab, Lenvatinib, Everolimus
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

NCT02421042
View directory record Official record
Conditions
Hepatic Impairment, Hepatic Function
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 11, 2026, 2:04 PM EDT
Recruiting Phase 2 Interventional

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

NCT06266338
View directory record Official record
Conditions
Cervix Cancer, Cervical Cancer
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Completed No phase listed Observational

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

NCT06345183
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma (aRCC)
Interventions
Nivolumab + Ipilimumab combination therapy, Pembrolizumab + Lenvatinib combination therapy
Combination Product
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 11, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

NCT04848337
View directory record Official record
Conditions
Prostate Cancer Metastatic, Neuroendocrine Tumors
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

NCT05308901
View directory record Official record
Conditions
Melanoma, Uveal
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

NCT01133977
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
Lenvatinib, Dacarbazine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Hagerstown, Maryland • Albany, New York • Greenville, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2016 · Synced Sep 11, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

NCT04955743
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

NCT04199104
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Lenvatinib, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Fresno, California • San Marcos, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

NCT03829332
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Anchorage, Alaska • Chandler, Arizona • Bakersfield, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Billings, Montana • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology

NCT00784303
View directory record Official record
Conditions
Thyroid Cancer
Interventions
Lenvatinib (DTC Cohort), Lenvatinib (MTC Cohort)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
23
States / cities
Little Rock, Arkansas • Los Angeles, California • Los Gatos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Sep 11, 2026, 2:04 PM EDT
Recruiting Phase 2 Interventional

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

NCT05064280
View directory record Official record
Conditions
Brain Metastases, Tumor
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

NCT03820986
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
17
States / cities
Los Angeles, California • San Francisco, California • Santa Monica, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 11, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

NCT04154189
View directory record Official record
Conditions
Osteosarcoma
Interventions
Lenvatinib, Ifosfamide, Etoposide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Loma Linda, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced Sep 11, 2026, 2:04 PM EDT